{
    "clinical_study": {
        "@rank": "144706", 
        "arm_group": [
            {
                "arm_group_label": "Group A (tacrolimus, methotrexate)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive tacrolimus IV over 24 hours beginning on day -1 and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11."
            }, 
            {
                "arm_group_label": "Group B (tacrolimus, methotrexate, mycophenolate mofetil)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive mycophenolate mofetil IV BID or PO BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD)."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and\n      methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate\n      in patients with hematologic malignancies undergoing allogeneic hematopoietic cell\n      transplant.  Both mycophenolate mofetil and reduced-dose methotrexate, in combination with a\n      calcineurin inhibitor, have been shown to be safe and effective in GVHD prevention with less\n      toxicity than standard dose methotrexate. It is not yet known, however, whether this\n      combination of mycophenolate mofetil and reduced-dose methotrexate with tacrolimus is more\n      effective than tacrolimus and standard dose methotrexate in preventing GVHD."
        }, 
        "brief_title": "Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention", 
        "completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Myelogenous Leukemia", 
            "Acute Lymphoblastic Leukemia", 
            "Acute Myeloid Leukemia", 
            "Acute Biphenotypic Leukemia", 
            "Myelodysplastic Syndrome", 
            "Myeloproliferative Neoplasm", 
            "Non-Hodgkin Lymphoma", 
            "Hodgkins Disease", 
            "Chronic Lymphocytic Leukemia", 
            "Multiple Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Graft vs Host Disease", 
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Biphenotypic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Myeloproliferative Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have one of the following documented diseases:\n\n               -  Chronic myelogenous leukemia\n\n               -  Chronic lymphocytic leukemia\n\n               -  Multiple myeloma\n\n               -  Myelodysplasia\n\n               -  Myeloproliferative disorder\n\n               -  Non-Hodgkin's lymphoma\n\n               -  Hodgkin's disease\n\n               -  Acute myelogenous leukemia\n\n               -  Acute lymphoblastic leukemia\n\n               -  Acute biphenotypic leukemia\n\n          -  Patients must be undergoing a myeloablative allogeneic hematopoietic cell transplant\n             with one of the following conditioning regimens:\n\n               -  Busulfan (>= 12.8 mg/kg IV or PO) and cyclophosphamide (>= 120 mg/kg)\n\n               -  Total body irradiation (TBI) (>= 1200 cGy) and etoposide (60 mg/kg)\n\n               -  TBI (>= 1200 cGy) and cyclophosphamide (120 mg/kg)\n\n          -  Patient must have achieved and be in complete morphologic remission prior to starting\n             conditioning regimen\n\n          -  Patient's donor must be a related or unrelated human leukocyte antigen (HLA) 8/8\n             allele-level match (HLA-A, B, C and DRB1)\n\n          -  Adult patients must have an Eastern Cooperative Oncology Group (ECOG) performance\n             status of 0 or 1; pediatric patients must have Lansky score >= 60%\n\n          -  Patients must have a life expectancy of 100 days\n\n          -  Patients must sign written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients who have undergone any prior transplant\n\n          -  Patients who are seropositive for human immunodeficiency virus (HIV)\n\n          -  Patients with any medical illness or concurrent psychiatric illness which, in the\n             investigators' opinion, cannot be adequately controlled with appropriate therapy\n\n          -  Patients who are pregnant or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951885", 
            "org_study_id": "CASE6Z13", 
            "secondary_id": [
                "NCI-2013-01800", 
                "CASE 6Z13", 
                "P30CA043703"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A (tacrolimus, methotrexate)", 
                    "Group B (tacrolimus, methotrexate, mycophenolate mofetil)"
                ], 
                "description": "Tacrolimus 0.03 mg/kg/day beginning day -1. Tac will be administered IV over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL", 
                "intervention_name": "tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": [
                    "FK 506", 
                    "Prograf"
                ]
            }, 
            {
                "arm_group_label": "Group A (tacrolimus, methotrexate)", 
                "description": "MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient < 10 kg then MTX will be given at 0.5 mg/kg IV on day +1.  Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "amethopterin", 
                    "Folex", 
                    "methylaminopterin", 
                    "Mexate", 
                    "MTX"
                ]
            }, 
            {
                "arm_group_label": "Group B (tacrolimus, methotrexate, mycophenolate mofetil)", 
                "description": "Mycophenolate 1000mg IV twice daily will begin on day +1, and will be converted to oral administration 1000 mg twice a day once patient can tolerate oral route. Patients<40 kg will receive MMF 45 mg/kg/day (15mg/kg IV three times a day).", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cellcept", 
                    "MMF"
                ]
            }, 
            {
                "arm_group_label": "Group B (tacrolimus, methotrexate, mycophenolate mofetil)", 
                "description": "MTX 5mg/m2 IV on day +1, +3, +6. If patient<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.", 
                "intervention_name": "Methotrexate (low dose)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "amethopterin", 
                    "Folex", 
                    "methylaminopterin", 
                    "Mexate", 
                    "MTX"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Mycophenolic Acid", 
                "Mycophenolate mofetil", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "hamiltb2@ccf.org", 
                    "last_name": "Betty Hamilton, MD", 
                    "phone": "216-444-2529"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Betty Hamilton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center"
                }, 
                "status": "Withdrawn"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease", 
        "other_outcome": {
            "description": "Donor chimerism will be assessed by analysis of single-tandem repeats on whole marrow and in lymphocyte enriched or sorted CD3+ T cells and CD33+ granulocytes. Blood will be obtained for donor chimerism \"Bone Marrow Engraftment analysis\" at approximately 1, 2, 3, 6, 9 and 12 months or as clinically indicated.", 
            "measure": "Chimerism results", 
            "safety_issue": "No", 
            "time_frame": "Up to one year"
        }, 
        "overall_official": {
            "affiliation": "Case Comprehensive Cancer Center", 
            "last_name": "Betty Hamilton, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Patients will be graded three times per week through day 28 of the study. Incidence will be compared through Wilcoxon rank sum tests.", 
                "measure": "Incidence of severe (grade 3-4) mucositis graded according to the World Health Organization (WHO) grading scale", 
                "safety_issue": "No", 
                "time_frame": "Up to day 28"
            }, 
            {
                "description": "The number of days to reach a neutrophil count of greater than or equal to 500/ul for three consecutive laboratory values obtained on different days. The day of engraftment will be the first day of the three consecutive laboratory values.", 
                "measure": "Time to neutrophil engraftment", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "The number of days to reach a platelet count of greater than or equal to 20,000/ul for three consecutive laboratory values obtained on different days, independent of platelet transfusions the prior 7 days. The day of engraftment will be the first day of the three consecutive laboratory values.", 
                "measure": "Time to platelet engraftment", 
                "safety_issue": "No", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "description": "Acute GVHD will be estimated using cumulative incidence methods and compared using the Pepe-Mori test.", 
                "measure": "Incidence of acute GVHD", 
                "safety_issue": "No", 
                "time_frame": "Day 7- Day 100"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hospital stay will be compared between patients in groups A and B using the Wilcoxon rank sum test.", 
                "measure": "Length of hospitalization", 
                "safety_issue": "No", 
                "time_frame": "Date of transplant to date of discharge, assessed up to 1 year"
            }, 
            {
                "description": "TPN and 100-day incidence of complications will be compared using the Chi-square test.", 
                "measure": "Use of total parenteral nutrition (TPN)", 
                "safety_issue": "No", 
                "time_frame": "Up to day 100"
            }, 
            {
                "description": "Estimated using the Kaplan-Meier method and compared between the 2 groups using the log-rank test.", 
                "measure": "Overall survival defined by Center for International Blood and Marrow Transplant Research (CIBMTR) criteria for individual diseases", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Estimated using the Kaplan-Meier method and compared between the 2 groups using the log-rank test.", 
                "measure": "Progression-free survival defined by CIBMTR criteria for individual diseases", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "description": "Chronic GVHD will be graded as mild, moderate, or severe based on the National Institutes of Health Consensus Development Project.The type and duration of immunosuppressive treatment given for cGVHD will be recorded.", 
                "measure": "Incidence of chronic GVHD", 
                "safety_issue": "No", 
                "time_frame": "after Day +100, every 3 months"
            }, 
            {
                "description": "Start and stop dates for the need of continuous IV infusion of narcotics for severe mucositis pain will be recorded. Time on IV infusion will be compared between patients in groups A and B using the Wilcoxon rank sum test.", 
                "measure": "Length of time on continuous infusion narcotics", 
                "safety_issue": "No", 
                "time_frame": "up to +28 day"
            }, 
            {
                "description": "TPN and 100-day incidence of infection will be compared using a Chi-square test. Infection will be monitored up to one year after transplantation", 
                "measure": "Incidence of infection", 
                "safety_issue": "No", 
                "time_frame": "Up to day +100"
            }, 
            {
                "description": "TPN and 100-day incidence of hepatotoxicity will be compared using a Chi-square test. Hepatotoxicity will be monitored up to one year after transplantation", 
                "measure": "Incidence of hepatotoxicity", 
                "safety_issue": "No", 
                "time_frame": "Up to day +100"
            }, 
            {
                "description": "TPN and 100-day incidence of nephrotoxicity will be compared using a Chi-square test. Nephrotoxicity will be monitored up to one year after transplantation", 
                "measure": "Incidence of nephrotoxicity", 
                "safety_issue": "No", 
                "time_frame": "Up to day +100"
            }, 
            {
                "description": "TPN and 180-day incidence of pulmonary toxicity will be compared using a Chi-square test. Pulmonary toxicity will be monitored up to one year after transplantation", 
                "measure": "Incidence of pulmonary toxicity", 
                "safety_issue": "No", 
                "time_frame": "Up to day +180"
            }
        ], 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}